Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 3;37(33):3142–3151. doi: 10.1200/JCO.19.00489

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by American Society of Clinical Oncology

PMC Copyright notice

FIG A3. — Kaplan Meier estimates for (A, C) L597 and (B, C) K601E mutated patients with BRAFi/MEKi combination and BRAFi or MEKi monotherapy for (A, B) progression-free survival (PFS) and (C, D) overall survival (OS). For non-V600 melanoma the two most frequent mutations were L597P/Q/R/S (15/38, 40%) and K601E (11/38, 29%). No significant differences were detected between the outcome for these unique non-V600 mutations compared with the full non-V600 cohort (PFS: L597 (P = .81); K601E (P = .004); OS: L597 (P = .57); K601E (P = .36).